IMPORT HIGH Ⅲ期随机试验中乳腺放疗加量后患者报告不良事件的5年趋势与基线预测因素
该研究基于 IMPORT HIGH Ⅲ期随机试验中接受乳腺放疗及瘤床加量的早期乳腺癌患者,分析患者报告不良事件(AE)的5年纵向变化及基线预测因素。结果显示,5年时35.4%患者无中度/重度AE,最常见为乳房外观整体改变(33.7%)和乳房变小(29.1%);手臂和乳房症状在6个月时达峰,乳房症状随后改善但手臂症状持续,年轻和焦虑是最常见的基线预测因素。
要点
- 5年时35.4%患者无中度/重度患者报告AE,最常见为乳房外观改变和乳房变小。
- 手臂与乳房症状在6个月评估时达峰,手臂症状持续至5年而乳房症状改善。
- 年轻和焦虑是AE发生的最常见基线预测因素,可指导支持策略。
核心结论
- 乳腺放疗加量后患者报告中度/重度AE数量至5年总体减少,但部分症状如手臂症状持续存在。
- 年轻和焦虑是AE发生的最常见基线预测因素。
研究设计与样本
- IMPORT HIGH(ISRCTN47437448)Ⅲ期随机试验中患者报告结局(PRO)子研究,纳入早期乳腺癌且局部复发风险高于平均的女性。
- 52/76个中心参与PRO子研究,1078/1338例患者知情同意;PRO采用EORTC QLQ-C30、QLQ-BR23和体像量表在基线、6个月、1年、3年、5年评估。
- AE按4点量表记录并二分为无/轻度 vs 中度/重度,采用广义估计方程分析模式与基线预测因素。
主要发现
- 5年时270/762(35.4%)患者无中度/重度AE。
- 5年时最常见中度/重度AE为乳房外观整体改变(257/762,33.7%)和乳房变小(222/762,29.1%)。
- 手臂和乳房症状在6个月评估时达峰,乳房症状随后改善但手臂症状持续至5年,体像相关AE较基线改善。
- 年轻和焦虑是最常见的AE基线预测因素。
临床怎么用
- 对接受全乳放疗加瘤床加量的患者,应关注年轻和焦虑等基线因素以制定支持策略。
- 随访中需注意手臂症状可能持续至5年,而乳房症状和体像相关AE可能随时间改善。
局限性
- PRO子研究仅纳入52/76个中心及1078/1338例患者,可能存在选择偏倚。
- AE采用4点量表二分为无/轻度 vs 中度/重度,可能损失细节信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: IMPORT HIGH demonstrated non-inferiority of simultaneous integrated boost against sequential boost for ipsilateral breast tumour relapse. Patient-reported adverse events (AEs) were similar across treatment groups. In this longitudinal analysis of patient-reported AE data from IMPORT HIGH we describe prevalence and baseline predictors of patient-reported AEs over 5-years. MATERIALS AND METHODS: IMPORT HIGH (ISRCTN47437448) recruited women with early breast cancer and higher-than-average local recurrence risk. All participants received breast radiotherapy and a boost. Patient-reported outcomes (PROs) were recorded using EORTC QLQ-C30, QLQ-BR23, Body Image Scale administered at baseline, 6 months, 1, 3, 5-years. AEs were recorded on a 4-point-scale and dichotomised (none/mild versus moderate/marked) for analysis. Generalised Estimating Equations assessed patterns of moderate/marked AEs and their baseline predictors. RESULTS: 52/76 IMPORT HIGH centres participated in the PRO sub-study. 1078/1338 patients consented. 270/762 (35.4 %) patients reported no moderate/marked AEs at 5-years. Most common moderate/marked AEs at 5-years were overall change in breast appearance (257/762, 33.7 %) and having a smaller breast (222/762, 29.1 %). Arm and breast symptoms peaked at 6-month assessment, with breast symptoms improving but arm symptoms persisting over 5-years. Body image-related AEs improved from baseline. Younger age and anxiety were the commonest baseline predictors of AEs. CONCLUSION: This longitudinal analysis of PROs in a large trial of breast and boost radiotherapy demonstrates an overall decrease in the number of patient-reported moderate/marked AEs up to 5-years following radiotherapy. Baseline factors predicting AE development include younger age and anxiety, informing support strategies for patients receiving whole breast and boost radiotherapy.
引用
- Ng S, Kilburn LS, Kirby AM, et al. Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial. Radiother Oncol. 2025. PMID: 40712928. doi:10.1016/j.radonc.2025.111056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。